Hegseth Testosterone Policy for Older Soldiers Challenged by Judge 2026

Pete Hegseth’s testosterone policy for older soldiers is under judicial scrutiny after a federal judge ordered the Pentagon to explain discrepancies with the treatment of transgender troops. The policy, announced earlier this month, requires male service members aged 30 and above to be screened for low testosterone levels and offers hormone replacement therapy (TRT) to volunteers.

What Is Hegseth’s Testosterone Policy?

Defense Secretary Pete Hegseth framed the initiative as a way to maintain “the leading edge of lethality” in the military. Under the plan, soldiers found to have below-normal testosterone can opt for TRT to boost muscle mass and bone density. Hegseth’s announcement, posted on X, used aggressive language consistent with the Trump administration’s rebranding of the Pentagon as the “Department of War.”

The policy applies to cisgender men 30 and older, but critics argue it creates a double standard. Federal Judge Ana Reyes, presiding over a lawsuit against Trump’s transgender troop ban, noted that the government promotes TRT for cisgender soldiers while using the need for hormone treatment to disqualify transgender troops.

Judge Orders Explanation

In her order, Judge Reyes requested detailed information on the Pentagon’s “basis for treating trans men and other service members differently between this new policy and the Military Ban.” She cited Trump’s executive order that bars transgender individuals from serving without “routine medical treatment or special provisions.” The Pentagon must answer questions about the cost, administration, and medical justification of TRT for older soldiers versus its stance on transgender troops.

Comparison of Treatment Policies

Key Takeaways

• Age threshold: The policy targets male service members aged 30 and above, screening for low testosterone.
• Voluntary TRT: Eligible soldiers can choose testosterone replacement therapy to improve physical readiness.
• Judicial challenge: A federal judge is forcing the Pentagon to justify why hormone treatment is acceptable for cisgender soldiers but not for transgender ones.
• Broader context: The controversy highlights ongoing tensions over transgender military service and health standards.
• Next steps: The Pentagon must respond to the judge’s order, potentially affecting both policies.

Why This Matters for Military Readiness

The debate over testosterone policy reflects deeper questions about how the military defines fitness and medical necessity. Supporters argue that optimizing hormone levels keeps soldiers combat-ready, especially as the average age of service members rises. Opponents warn that the policy undermines equal treatment and could lead to discrimination based on gender identity.

As the court reviews the discrepancy, the Trump administration faces pressure to clarify its stance. The outcome could reshape medical protocols for all troops, not just those over 30.

FAQ